Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma.
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal
/ administration & dosage
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Female
Humans
Immunoconjugates
/ administration & dosage
Lung Neoplasms
/ drug therapy
Male
Middle Aged
Neoplasm Staging
Proto-Oncogene Proteins c-met
/ drug effects
Time Factors
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
received:
26
02
2021
revised:
11
06
2021
accepted:
16
08
2021
pubmed:
25
8
2021
medline:
1
4
2022
entrez:
24
8
2021
Statut:
ppublish
Résumé
Telisotuzumab vedotin (Teliso-V) is an anti-c-Met-directed antibody-drug conjugate. Here, we present safety and efficacy data from a phase I/Ib study of Teliso-V monotherapy evaluated in once every 2 weeks/once every 3 weeks schedules in patients with non-small cell lung cancer (NSCLC). During dose escalation, patients received Teliso-V monotherapy intravenously once every 3 weeks (0.15-3.3 mg/kg) or once every 2 weeks (1.6-2.2 mg/kg). The dose-expansion phase enrolled patients with NSCLC and c-Met Fifty-two patients with NSCLC were enrolled and received ≥1.6 mg/kg Teliso-V once every 2 weeks ( Teliso-V monotherapy was tolerated and showed antitumor activity in c-Met+ NSCLC. On the basis of overall safety, pharmacokinetics, and efficacy outcomes, 1.9 mg/kg Teliso-V once every 2 weeks and 2.7 mg/kg once every 3 weeks schedules were selected for further clinical development.
Identifiants
pubmed: 34426443
pii: 1078-0432.CCR-21-0765
doi: 10.1158/1078-0432.CCR-21-0765
pmc: PMC9401525
doi:
Substances chimiques
Antibodies, Monoclonal
0
Immunoconjugates
0
telisotuzumab vedotin
976X9VXC3Z
MET protein, human
EC 2.7.10.1
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Banques de données
ClinicalTrials.gov
['NCT02099058']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5781-5792Informations de copyright
©2021 The Authors; Published by the American Association for Cancer Research.
Références
Clin Cancer Res. 2004 May 1;10(9):3069-75
pubmed: 15131045
Int J Cancer. 2005 Feb 10;113(4):678-82
pubmed: 15455388
J Hematol Oncol. 2016 Aug 05;9(1):66
pubmed: 27496196
J Clin Oncol. 2017 Feb;35(4):412-420
pubmed: 27937096
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
Mol Cancer Ther. 2020 May;19(5):1210-1217
pubmed: 32127466
Clin Cancer Res. 2016 Jun 15;22(12):3048-56
pubmed: 26847053
J Clin Oncol. 2014 Nov 10;32(32):3659-66
pubmed: 25267741
Jpn J Clin Oncol. 1997 Dec;27(6):378-83
pubmed: 9437998
Lung Cancer. 2018 Sep;123:76-82
pubmed: 30089599
Mayo Clin Proc. 2008 May;83(5):584-94
pubmed: 18452692
Cancer Cell. 2010 Jan 19;17(1):77-88
pubmed: 20129249
Invest New Drugs. 2018 Feb;36(1):121-135
pubmed: 29027591
J Thorac Oncol. 2017 Jan;12(1):141-144
pubmed: 27664533
J Clin Oncol. 2015 Aug 20;33(24):2667-74
pubmed: 26169611
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Cancer Res. 2005 Feb 15;65(4):1479-88
pubmed: 15735036
J Clin Oncol. 2018 Nov 20;36(33):3298-3306
pubmed: 30285518
BMC Cancer. 2016 Feb 16;16:105
pubmed: 26879245
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Clin Cancer Res. 2017 Feb 15;23(4):992-1000
pubmed: 27573171
N Engl J Med. 2010 Nov 4;363(19):1812-21
pubmed: 21047225
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Eur J Cancer. 2017 Dec;87:131-139
pubmed: 29145039
Clin Lung Cancer. 2021 May;22(3):170-177
pubmed: 33221175
Lung Cancer. 2019 Jul;133:96-102
pubmed: 31200835
J Thorac Oncol. 2016 Apr;11(4):556-65
pubmed: 26724471
Clin Cancer Res. 2019 Apr 15;25(8):2403-2413
pubmed: 30425090
Cancer Res. 2007 Feb 15;67(4):1670-9
pubmed: 17308108
Oncotarget. 2016 May 24;7(21):31029-36
pubmed: 27105539
Cancer Metastasis Rev. 2003 Dec;22(4):309-25
pubmed: 12884908
Clin Cancer Res. 2012 Jan 1;18(1):248-55
pubmed: 22080439
J Clin Oncol. 2013 Nov 10;31(32):4105-14
pubmed: 24101053
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
J Clin Oncol. 2009 Apr 1;27(10):1667-74
pubmed: 19255323
J Clin Oncol. 2008 Oct 1;26(28):4617-25
pubmed: 18678835